EZH2抑制剂治疗复发/难治性外周T细胞淋巴瘤1例并文献复习

doi:10.3760/cma.j.cn441417-20250110-13029

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (13): 2256-2259.DOI: 10.3760/cma.j.cn441417-20250110-13029

EZH2抑制剂治疗复发/难治性外周T细胞淋巴瘤1例并文献复习

仉紫薇颜嘉欣高娜

滨州医学院附属医院血液内科，滨州 256603

收稿日期:2025-01-10 出版日期:2025-07-01 发布日期:2025-08-04
通讯作者: 高娜，Email：gn2882155@163.com
基金资助:
北京吴阶平医学基金会资助项目

A case of relapsed/refractory peripheral T-cell lymphoma treated with EZH2 inhibitors and literature review

Zhang Ziwei, Yan Jiaxin, Gao Na

Department of Hematology, Affiliated Hospital of Binzhou Medical University, Binzhou 256603, China

Received:2025-01-10 Online:2025-07-01 Published:2025-08-04
Contact: Gao Na, Email: gn2882155@163.com
Supported by:
Project funded by Beijing Wu Jieping Medical Foundation

摘要/Abstract

摘要：

本文报道了1例Zeste增强子同源物2（enhancer of zeste homolog 2，EZH2）抑制剂治疗复发/难治性外周T细胞淋巴瘤患者。外周T细胞淋巴瘤是一组起源于胸腺后成熟T细胞或成熟NK细胞罕见的、具有高度异质性和侵袭性的淋巴组织增生性疾病，整体预后差，一线治疗后复发率高。复发/难治性外周T细胞淋巴瘤治疗选择很少。EZH2是一种组蛋白甲基转移酶，广泛存在于多种肿瘤细胞中，EZH2表达与外周T细胞淋巴瘤进展、预后不良有关。因此，抑制EZH2活性已成为复发/难治性外周T细胞淋巴瘤的治疗靶点。

关键词: 外周T细胞淋巴瘤, 复发, Zeste增强子同源物2抑制剂

Abstract:

This article reports a case of relapsed/refractory peripheral T-cell lymphoma treated with an enhancer of zeste homolog 2 (EZH2) inhibitor. Peripheral T-cell lymphoma is a rare and highly heterogeneous and aggressive lymphoproliferative disease originating from post-thymic mature T cells or mature NK cells, characterized by a poor overall prognosis and a high recurrence rate after first-line treatment. There are limited treatment options for relapsed/refractory peripheral T-cell lymphoma. EZH2 is a histone methyltransferase widely expressed in various tumor cells, and its expression is associated with the progression and poor prognosis of peripheral T-cell lymphoma. Therefore, inhibiting EZH2 activity has become a therapeutic target for relapsed/refractory peripheral T-cell lymphoma.

Key words: Peripheral T-cell lymphoma, , Recurrence, , Zeste enhancer homolog 2 inhibitors

仉紫薇颜嘉欣高娜.

EZH2抑制剂治疗复发/难治性外周T细胞淋巴瘤1例并文献复习 [J]. 国际医药卫生导报, 2025, 31(13): 2256-2259.

Zhang Ziwei, Yan Jiaxin, Gao Na.

A case of relapsed/refractory peripheral T-cell lymphoma treated with EZH2 inhibitors and literature review [J]. International Medicine and Health Guidance News, 2025, 31(13): 2256-2259.

参考文献

[1]Alaggio R, Amador C, Anagnostopoulos I, A et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms[J]. Leukemia, 2022, 36(7): 1720-1748. DOI: 10.1038/s41375-022-01620-2.

[2]Vose J, Armitage J, Weisenburger D, et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes[J]. J Clin Oncol, 2008, 26(25): 4124-4130. DOI: 10.1200/JCO.2008.16.4558.

[3]Zing NPC, Fischer T, Zain J, et al. Peripheral T-cell lymphomas: incorporating new developments in diagnostics, prognostication, and treatment into clinical practice-part 1: PTCL-NOS, FTCL, AITL, ALCL[J]. Oncology (Williston Park), 2018, 32(7): e74-e82.

[4]Fiore D, Cappelli LV, Broccoli A, et al. Peripheral T cell lymphomas: from the bench to the clinic[J]. Nat Rev Cancer, 2020, 20(6): 323-342. DOI: 10.1038/s41568-020-0247-0.

[5]Luan Y, Li X, Luan Y, et al. Therapeutic challenges in peripheral T-cell lymphoma[J]. Mol Cancer, 2024, 23(1): 2. DOI: 10.1186/s12943-023-01904-w.

[6]Bellei M, Chiattone CS, Luminari S, et al. T-cell lymphomas in South America and Europe[J]. Rev Bras Hematol Hemoter, 2012, 34(1): 42-47. DOI:10.5581/1516-8484.20120013.

[7]Oluwasanjo A, Kartan S, Johnson W, et al. Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) [J]. Cancer Treat Res, 2019, 176: 83-98. DOI: 10.1007/978-3-319-99716-2_4.

[8]Lansigan F, Horwitz SM, Pinter-Brown LC, et al. Outcomes for relapsed and refractory peripheral T-cell lymphoma patients after front-line therapy from the COMPLETE registry[J]. Acta Haematol, 2020, 143(1): 40-50. DOI: 10.1159/000500666.

[9]Liu Y, Yang Q. The roles of EZH2 in cancer and its inhibitors[J]. Med Oncol, 2023,40(6): 167. DOI:10.1007/s12032-023-02025-6.

[10]Pasini D, Di Croce L. Emerging roles for polycomb proteins in cancer[J]. Curr Opin Genet Dev, 2016, 36: 50-58. DOI:10.1016/j.gde.2016.03.013.

[11]Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics[J]. Mutat Res, 2008, 647(1-2): 21-29. DOI: 10.1016/j.mrfmmm.2008.07.010.

[12]Xu K, Wu ZJ, Groner AC, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent[J]. Science, 2012, 338(6113): 1465-1469. DOI: 10.1126/science.1227604.

[13]Kim E, Kim M, Woo DH, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells[J]. Cancer Cell, 2013, 23(6): 839-852. DOI: 10.1016/j.ccr.2013.04.008.

[14]Kim J, Lee Y, Lu X, et al. Polycomb- and methylation-independent roles of EZH2 as a transcription activator[J]. Cell Rep, 2018, 25(10): 2808-2820.e4. DOI: 10.1016/j.celrep.2018.11.035.

[15]Zimmerman SM, Lin PN, Souroullas GP. Non-canonical functions of EZH2 in cancer[J]. Front Oncol, 2023, 13: 1233953. DOI: 10.3389/fonc.2023.1233953.

[16]Kim KH, Roberts CW. Targeting EZH2 in cancer[J]. Nat Med, 2016, 22(2): 128-134. DOI: 10.1038/nm.4036.

[17]Shi M, Shahsafaei A, Liu C, et al. Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases[J]. Leuk Lymphoma, 2015, 56(7): 2087-2091. DOI: 10.3109/10428194.2014.968780.

[18]Jiang T, Wang Y, Zhou F, et al. Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis[J]. Oncotarget, 2016 , 7(4):4584-4597. DOI: 10.18632/oncotarget.6612.

[19]Tian X, Pelton A, Shahsafaei A, et al. Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas[J]. Mod Pathol, 2016,29(9): 1050-1057. DOI:10.1038/modpathol.2016.114.

[20]Herviou L, Cavalli G, Cartron G, et al. EZH2 in normal hematopoiesis and hematological malignancies[J]. Oncotarget, 2016, 7(3): 2284-2296. DOI: 10.18632/oncotarget.6198.

[21]Tian X, Xu J, Fletcher C, et al. Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling[J]. Mod Pathol, 2018, 31(4):553-561. DOI: 10.1038/modpathol.2017.174.

[22]Tian X, Xu J, Dorfman DM. Utility of combined EZH2, p-ERK1/2, p-STAT, and MYC expression in the differential diagnosis of EZH2-positive hodgkin lymphomas and related large B-cell lymphomas[J]. Am J Surg Pathol, 2019, 43(1):102-109. DOI: 10.1097/PAS.0000000000001180.

[23]Martinez-Baquero D, Sakhdari A, Mo H, et al. EZH2 expression is associated with inferior overall survival in mantle cell lymphoma[J]. Mod Pathol, 2021, 34(12): 2183-2191. DOI: 10.1038/s41379-021-00885-9.

[24]Fujikawa D, Nakagawa S, Hori M, et al. Polycomb-dependent epigenetic landscape in adult T-cell leukemia[J]. Blood, 2016, 127(14): 1790-1802. DOI: 10.1182/blood-2015-08-662593.

[25]Song Y, Jin Z, Li ZM, et al. Enhancer of zeste homolog 2 inhibitor SHR2554 in relapsed or refractory peripheral T-cell lymphoma: data from the first-in-human phase I study[J]. Clin Cancer Res, 2024, 30(7): 1248-1255. DOI: 10.1158/1078-0432.CCR-23-2582.

EZH2抑制剂治疗复发/难治性外周T细胞淋巴瘤1例并文献复习

A case of relapsed/refractory peripheral T-cell lymphoma treated with EZH2 inhibitors and literature review

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	薛媛王东张杰闫娟李二乐拓明祥. 中耳炎患者耳内镜手术后复发情况及预测模型构建 [J]. 国际医药卫生导报, 2025, 31(6): 1041-1046.
[2]	思雅芳刘瑜瑜曹丽. 不同剂量利妥昔单抗治疗特发性膜性肾病的效果及复发影响因素分析 [J]. 国际医药卫生导报, 2025, 31(5): 723-728.
[3]	莫家婵范万峰姜兴岳. 基于磁共振成像的影像组学在垂体腺瘤中的应用现状及进展 [J]. 国际医药卫生导报, 2025, 31(5): 757-760.
[4]	杨尚云佘雯许诚. CEUS与二维超声预测肝癌US-PMMA治疗后复发的价值 [J]. 国际医药卫生导报, 2025, 31(10): 1646-1650.
[5]	张秀玲韩志红戴旭. 地诺孕素与GnRH-a对卵巢子宫内膜异位囊肿术后疼痛和复发率的影响[J]. 国际医药卫生导报, 2025, 31(1): 26-30.
[6]	钟细芳曾彩玲钟秋明陈荟. IKAP模式为指导的家长教育课堂在儿童特应性皮炎防治管理中的应用 [J]. 国际医药卫生导报, 2025, 31(1): 159-162.
[7]	岳红陈文华范志刚张淑莲常捷芳. 贝伐珠单抗联合TC方案治疗晚期复发性卵巢癌患者的效果 [J]. 国际医药卫生导报, 2024, 30(7): 1190-1194.
[8]	刘琪亮李碧娥邵海宾冷嫦娥夏长普麦熙. 小柴胡汤治疗少阳失枢轻型复发性口腔溃疡患者的临床效果 [J]. 国际医药卫生导报, 2024, 30(23): 3988-3991.
[9]	冯畅唐亚华叶桂林. 输尿管硬镜下钬激光碎石术治疗复杂性上尿路结石的疗效 [J]. 国际医药卫生导报, 2024, 30(22): 3816-3820.
[10]	张一丹吴树腾周丹. 不明原因复发性流产患者胸腺和胸腺外来源的调节性T细胞表达及检测意义 [J]. 国际医药卫生导报, 2024, 30(21): 3614-3618.
[11]	张琳高艾玲何祥一. 白芍总苷胶囊联合益生菌芦荟发酵凝胶治疗复发性阿弗他溃疡的疗效分析 [J]. 国际医药卫生导报, 2024, 30(21): 3675-3679.
[12]	侯永志芦杰王文玉. 128排CT灌注成像在浸润性肺腺癌患者术后复发预测中的临床价值 [J]. 国际医药卫生导报, 2024, 30(18): 3058-3062.
[13]	郭超闫书贤李淑华杨兴强邢东亮. 输尿管软镜碎石取石术对男性肾结石患者肾功能、疼痛应激的影响 [J]. 国际医药卫生导报, 2024, 30(18): 3098-3102.
[14]	李强田阳涛. 分化型甲状腺癌患者腔镜术后复发的智能预测系统构建 [J]. 国际医药卫生导报, 2024, 30(17): 2883-2888.
[15]	吴庆华郝红李雪雪韩晨博. 外周血NLR联合CD8⁺ T淋巴细胞对乳腺癌患者保乳术后复发的预测价值 [J]. 国际医药卫生导报, 2024, 30(15): 2474-2479.